Revance Therapeutics, Inc. is a United States-based specialty biopharmaceutical company. The Company develops botulinum toxin products for use in aesthetic and therapeutic indications. The Company has developed a platform technology, TransMTS, which enables local, targeted delivery of botulinum toxin and other macromolecules across skin without patches. The Company's investigational product is a topically applied botulinum toxin type A (BoNTA). Its investigational product, RT001 (botulinum toxin type A) Topical Gel, is designed to reduce crow's feet wrinkles by relaxing the muscles around the eye. RT001, a topically applied botulinum toxin type A, is under investigation for the treatment of hyperhidrosis, or excessive sweating.